Although it is unclear whether the mechanism of entrectinib action is mainly via ALK or TRK, this patient represents the first reported case of a 2p gain ALKAL2 ligand variant, which potentially drives ALK pathway activation in NB. This evidence concerns the gene NTRK1 and neuroblastoma.